文献速递头颈与中枢神经肿瘤

生物标志物预测阿法替尼对比甲氨蝶呤在二线复发/转移性头颈癌中的疗效

Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer.
PubMed 文献 · Ann Oncol · 2017-01-01

基于III期LUX-Head & Neck 1试验,483例随机患者中326例纳入生物标志物分析。p16阴性、EGFR扩增、HER3低表达和PTEN高表达肿瘤患者中,阿法替尼较甲氨蝶呤延长中位PFS。p16阴性且EGFR扩增联合亚组及p16阴性且EGFR治疗初治亚组中,阿法替尼同样改善PFS。

要点

  • p16阴性患者中阿法替尼较甲氨蝶呤改善PFS:2.7 vs 1.6个月,HR 0.70。
  • EGFR扩增患者中阿法替尼较甲氨蝶呤改善PFS:2.8 vs 1.5个月,HR 0.53。
  • p16阴性且EGFR扩增联合亚组中阿法替尼较甲氨蝶呤改善PFS:2.7 vs 1.5个月,HR 0.47。

核心结论

  • 基于预设肿瘤生物标志物(p16阴性、EGFR扩增、HER3低表达、PTEN高表达)可识别可能从阿法替尼获得更多获益的HNSCC亚组。
  • 未来研究需要验证这些发现。

研究设计与样本

  • III期LUX-Head & Neck 1(LUX-H&N1)试验,随机患者接受阿法替尼(40 mg/天)或甲氨蝶呤(40 mg/m2/周)。
  • 483例随机患者中326例(67%)纳入生物标志物分析,基线特征与总体研究人群一致。
  • 肿瘤生物标志物(p16、EGFR、HER2、HER3、c-MET、PTEN)采用组织微阵列核心和切片评估;血清蛋白采用VeriStrat®检测。

主要发现

  • p16阴性肿瘤患者中位PFS:阿法替尼2.7个月 vs 甲氨蝶呤1.6个月,HR 0.70(95% CI 0.50-0.97)。
  • EGFR扩增肿瘤患者中位PFS:阿法替尼2.8个月 vs 甲氨蝶呤1.5个月,HR 0.53(95% CI 0.33-0.85)。
  • HER3低表达肿瘤患者中位PFS:阿法替尼2.8个月 vs 甲氨蝶呤1.8个月,HR 0.57(95% CI 0.37-0.88)。
  • PTEN高表达肿瘤患者中位PFS:阿法替尼1.6个月 vs 甲氨蝶呤1.4个月,HR 0.55(95% CI 0.29-1.05)。
  • p16阴性且EGFR扩增联合亚组中位PFS:阿法替尼2.7个月 vs 甲氨蝶呤1.5个月,HR 0.47(95% CI 0.28-0.80);p16阴性且EGFR治疗初治亚组中位PFS:阿法替尼4.0个月 vs 甲氨蝶呤2.4个月,HR 0.55(95% CI 0.31-0.98)。

关键数值与推荐

  • 预设生物标志物亚组:p16(所有肿瘤亚部位)、EGFR、HER2、HER3、c-MET、PTEN。
  • 阿法替尼剂量40 mg/天;甲氨蝶呤剂量40 mg/m2/周。
  • VeriStrat 'Good' vs 'Poor' 的阿法替尼治疗患者中位PFS:2.7 vs 1.5个月,HR 0.71(95% CI 0.49-0.94),但未观察到治疗交互作用。
  • 除p16阳性疾病(n=35)外,阿法替尼在所有分析亚组中均较甲氨蝶呤改善肿瘤缓解。

临床怎么用

  • 对于二线复发/转移性HNSCC患者,检测p16、EGFR扩增、HER3和PTEN表达可能有助于识别从阿法替尼获益更多的亚组。
  • p16阴性且EGFR扩增或EGFR治疗初治患者中,阿法替尼较甲氨蝶呤显示更优PFS。
  • p16阳性患者(n=35)中阿法替尼未显示肿瘤缓解改善。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the phase III LUX-Head & Neck 1 (LUX-H&N1) trial, second-line afatinib significantly improved progression-free survival (PFS) versus methotrexate in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Here, we evaluated association of prespecified biomarkers with efficacy outcomes in LUX-H&N1. PATIENTS AND METHODS: Randomized patients with R/M HNSCC and progression following ≥2 cycles of platinum therapy received afatinib (40 mg/day) or methotrexate (40 mg/m2/week). Tumor/serum samples were collected at study entry for patients who volunteered for inclusion in biomarker analyses. Tumor biomarkers, including p16 (prespecified subgroup; all tumor subsites), EGFR, HER2, HER3, c-MET and PTEN, were assessed using tissue microarray cores and slides; serum protein was evaluated using the VeriStrat® test. Biomarkers were correlated with efficacy outcomes. RESULTS: Of 483 randomized patients, 326 (67%) were included in the biomarker analyses; baseline characteristics were consistent with the overall study population. Median PFS favored afatinib over methotrexate in patients with p16-negative [2.7 versus 1.6 months; HR 0.70 (95% CI 0.50-0.97)], EGFR-amplified [2.8 versus 1.5 months; HR 0.53 (0.33-0.85)], HER3-low [2.8 versus 1.8 months; HR 0.57 (0.37-0.88)], and PTEN-high [1.6 versus 1.4 months; HR 0.55 (0.29-1.05)] tumors. Afatinib also improved PFS in combined subsets of patients with p16-negative and EGFR-amplified tumors [2.7 versus 1.5 months; HR 0.47 (0.28-0.80)], and patients with p16-negative tumors who were EGFR therapy-naïve [4.0 versus 2.4 months; HR 0.55 (0.31-0.98)]. PFS was improved in afatinib-treated patients who were VeriStrat 'Good' versus 'Poor' [2.7 versus 1.5 months; HR 0.71 (0.49-0.94)], but no treatment interaction was observed. Afatinib improved tumor response versus methotrexate in all subsets analyzed except for those with p16-positive disease (n = 35). CONCLUSIONS: Subgroups of HNSCC patients who may achieve increased benefit from afatinib were identified based on prespecified tumor biomarkers (p16-negative, EGFR-amplified, HER3-low, PTEN-high). Future studies are warranted to validate these findings. CLINICAL TRIAL REGISTRATION: NCT01345682.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cohen EEW, Licitra LF, Burtness B, et al. Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer. Ann Oncol. 2017. PMID: 28961833. doi:10.1093/annonc/mdx344

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。